Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Gallbladder Neoplasms 2Cholangiocarcinoma 2Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 9Carboplatin 9Taxes 7Paclitaxel 7Biopsy 7temsirolimus 6Trastuzumab 5Sirolimus 5pembrolizumab 4Radiotherapy 4olaparib 3Nivolumab 3Interleukin-12 Subunit p35 3Bevacizumab 3pertuzumab 2palbociclib 2ipatasertib 2binimetinib 2aldesleukin 2X-Rays 2Thalidomide 2Reverse Transcriptase Polymerase Chain Reaction 2Oxaliplatin 2Megestrol Acetate 2Interleukin-12 2Immunoglobulin G 2Fluorouracil 2Docetaxel 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Endometrial Neoplasms × cobimetinib × Clear all
NCT05691504 2026-05-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

National Cancer Institute (NCI)

Phase 1 Active not recruiting
42 enrolled
GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡